Why a leading broker is bullish on these 3 ASX shares

These ASX shares could be heading higher…

| More on:
A man with a wide, eager smile on his face holds up three fingers.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you have room for some new portfolio additions, then it could be worth considering the three ASX shares listed below.

Here's why analysts at Morgans are bullish on these shares:

QBE Insurance Group (ASX: QBE)

Morgans is feeling positive about this insurance giant's shares. It currently has an add rating and $13.70 price target on them.

The broker believes QBE's shares are trading at an attractive level. Particularly given its balance sheet and the outlook for premium increases.

It said: "We see QBE as likely having positive underlying momentum into next year. QBE has been putting through top-line rate increases of around 9%, which should assist margin expansion into FY22. With QBE's balance sheet recently reset, pricing tailwinds evident and the stock relatively inexpensive trading on ~12.9x FY22F PE."

ResMed Inc (ASX: RMD)

Morgans is a fan of ResMed. Its analysts currently have an add rating and $40.80 price target on its shares.

The broker likes ResMed due to its very positive medium to long term outlook, which is being underpinned by its digital platform.

Morgans commented: "While we believe the next few quarters will likely be volatile, as COVID-related demand for ventilators continues to slow and core sleep apnoea volumes gradually lift, nothing changes our medium/longer term view that the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain."

Sonic Healthcare (ASX:SHL)

Finally, this healthcare share is another that Morgans rates highly. The broker currently has an add rating and $47.05 price target on its shares.

Morgans is positive on Sonic due largely to its belief that COVID testing will remain strong for the foreseeable future. It also notes that its strong balance sheet opens up M&A opportunities.

Its analysts explained: "We see COVID-19 testing continuing into the foreseeable future, with growth potential in COVID serology testing. SHL's global base business is increasingly resilient, benefitting from geographical diversity. Strong B/S (gearing 21.6x; A$1.3bn headroom) opening the door to acquisitions, contracts and JVs [joint ventures]."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Man looking at digital holograms of graphs, charts, and data.
Broker Notes

3 reasons this ASX 300 tech stock is forecast to leap 83% in 2026

A leading broker expects some outsized returns from this ASX 300 tech share. Let’s see why.

Read more »

gold share price represented by speeding golden bullet
Broker Notes

Why this surging ASX All Ords gold stock is tipped to rocket another 233%

A leading broker expects outsized gains from this ASX All Ords gold stock. But not without risk.

Read more »

A blockchain investor sits at his desk with a laptop computer open and a phone checking information from a booklet in a home office setting.
Broker Notes

3 buy-rated ASX 300 shares at 52-week lows

They've fallen far over the past 12 months but have buy ratings from the experts.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Broker Notes

Bell Potter names more of the best ASX 200 shares to buy in December

These are best buys according to the broker. Here's what it is saying about them.

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 30% to 40% in 2026

Looking for big returns? Analysts think these shares could beat the market.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Broker Notes

Analysts name 3 ASX shares to buy this week

Analysts have good things to say about these shares.

Read more »

Three guys in shirts and ties give the thumbs down.
Broker Notes

Experts name 3 popular 200 ASX shares to sell now

Let's find out why analysts are feeling bearish about these shares.

Read more »

Five happy miners standing next to each other representing ASX coal mining shares which some brokers say could pay big dividends this year
Broker Notes

7 ASX mining shares to buy for Christmas amid upgrades from Macquarie

Macquarie has boosted its outlook for these seven ASX mining stocks. Let’s see why.

Read more »